The FDA has cleared a new blood test to aid in the evaluation of Alzheimer's disease, marking a significant advancement in early detection and diagnosis. This breakthrough could simplify screening and expand access to early intervention, as current diagnostic methods often require invasive procedures or expensive imaging.
Background
Alzheimer's disease is the most common form of dementia, affecting millions worldwide. Current diagnosis relies on cognitive assessments, PET scans, and cerebrospinal fluid analysis, but blood-based biomarkers represent a promising shift toward less invasive screening.
- Source
- Hacker News (RSS)
- Published
- Aug 24, 2026 at 02:30 PM
- Score
- 8.0 / 10